A clinical stage biotech based in San Diego with a broad portfolio in immuno-oncology driven by our proprietary bispecific platforms for construction of native IgG-like bispecifics with enhanced manufacturability.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
PT199 anti-CD73 mAb, PT886 anti-claudin18.2/anti-CD47 and PT217 anti-DLL3/anti-CD47 bispecifics
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
